Illumina Inc. closed $13.90 short of its 52-week high ($144.02), which the company achieved on January 31st.

GRAIL faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Click here to ...

On Thursday, Illumina Inc (ILMN) stock saw a modest uptick, ending the day at $132.27 which represents a slight increase of $6.12 or 4.85% from the prior close of $126.15. The stock opened at $128.04 ...

The stock's rise snapped a four-day losing streak.

Illumina Inc (ILMN) stock saw a decline, ending the day at $128.82 which represents a decrease of $-1.28 or -0.98% from the prior close of $130.1. The stock opened at $130.49 and touched a low of $128 ...

Investors have circled back to healthcare stocks this year, and they’re likely to stick around. If they came for the ...

Illumina (NASDAQ: ILMN) a global leader in genomics, and LGC Biosearch Technologies™, a pioneer in agricultural genomics, ...

The Dutch competition watchdog is seeking beefed-up powers to probe more small deals that risk crushing competition in ...

2 Since then, aside from the Illumina/Grail transaction, the Commission called in a small number of concentrations. The ...

Leerink Partners analyst Puneet Souda reiterated a Buy rating on Quanterix (QTRX – Research Report) today. The company’s shares ...

Shareholders are set to vote on Thursday whether to back the gene-sequencing company’s incumbent board ... authority blocked a merger of Illumina and Grail, even though Illumina said Grail ...

CHICAGO--(BUSINESS WIRE)--Syntax Bio, a preclinical-stage biotechnology company, has launched with backing from Astellas Venture Management LLC and Illumina Ventures. Other investors include ...